Generic switching in Japan has significant impact on medical costs

7 March 2018

Japan’s switch to generic drugs from brand-name medicines is expected to have reduced the country’s medical costs by 1.3 trillion yen ($12. 3 billion) in fiscal 2017, according to a Ministry of Health, Labor and Welfare (MHLW) announcement reported by local media.

The reduction, the biggest on record, would be about 40% greater than estimated for fiscal 2015, according to the Japan Times.

The government aims to raise the share of generic drugs in use to at least 80% by September 2020 based on a projection showing that 1.3 trillion yen in medical costs could be saved per year if the target is met.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK